Loading stock data…
TG Therapeutics (TGTX)
$55.75-0.08 (-0.14%)
Market OpenUpdated 3:08 PM EDT
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TG Therapeutics, Inc. in the Healthcare sector is trading at $55.75 with a market capitalization of $7.6B. Wall Street consensus targets $51.71 (7 analysts), implying a -7.2% move over the next 12 months. The stock is currently near its 52-week high of $57.38, remaining 62.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -7.2% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $204.92M↑ | $192.57M↑ | $161.71M↑ | $141.15M↑ | $120.86M |
| Gross Profit | $171.41M↑ | $154.43M↑ | $133.62M↑ | $122.21M↑ | $105.31M |
| Operating Income | $34.80M↓ | $50.49M↑ | $29.36M↓ | $34.84M↑ | $8.62M |
| Net Income | $19.78M↓ | $23.04M↓ | $390.89M↑ | $28.19M↑ | $5.06M |
Peer Comparison
JNJUNHPFE
Fundamentals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMV...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.59B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
79.21%
Volume
Today's trading volume
1.22M
Recent News
Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?
Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on TGTX. TG Therapeutics, Inc.’s share was trading at $50.54 as of June 16th. TGTX’s trailing and forward P/E were 17.59 and 38.76 respectively according to Yahoo Finance. […]
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 79% And Climbing
TG Therapeutics stock is on an absolute rampage, climbing 79% in roughly the first six months of the year, as the biotech takes on Roche.
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data
Recent announcements from TG Therapeutics have buoyed optimism on the long-term potential of its Briumvi drug.
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Association 2026 Congress taking place on June 11-14, 2026, in Stockholm, Sweden. The global TENACITY-01 study had an 85.7% overall response rate, with a complete remission rate of 71.4% in adults […] The post Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates appeared first on ExecEdge.